US FDA cites 4 deaths in Newron's schizophrenia drug trial hold

2

Oct 8 (Reuters) – Italy's Newron Pharmaceuticals said on Thursday the FDA had outlined safety concerns behind a clinical hold at US sites in a late-stage trial of its experimental schizophrenia drug,

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)